Perceptive Advisors’s Protara Therapeutics TARA Stock Holding History

Perceptive Advisors’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-290,051	Closed	-$908K	–	105
2023 Q1	$908K	Hold	290,051	–	–	0.03%	94
2022 Q4	$777K	Hold	290,051	–	–	0.02%	92
2022 Q3	$859K	Hold	290,051	–	–	0.02%	105
2022 Q2	$850K	Sell	290,051 -93,475	-24%	-$342K	0.03%	103
2022 Q1	$1.96M	Sell	383,526 -38,115	-9%	-$200K	0.04%	119
2021 Q4	$2.85M	Hold	421,641	–	–	0.04%	131
2021 Q3	$2.92M	Hold	421,641	–	–	0.04%	128
2021 Q2	$4.11M	Sell	421,641 -1	-0%	-$11	0.05%	128
2021 Q1	$6.64M	Sell	421,642 -186,902	-31%	-$3.47M	0.08%	106
2020 Q4	$14.7M	Hold	608,544	–	–	0.16%	97
2020 Q3	$10.2M	Buy	+608,544	New	+$14.1M	0.15%	88
2020 Q2	–	Sell	-8,543	Closed	-$184K	–	138
2020 Q1	$184K	Sell	8,543 -1	-0%	-$29	﹤0.01%	108
2019 Q4	$140K	Buy	+8,544	New	+$98K	﹤0.01%	110
2018 Q4	–	Sell	-6,012	Closed	-$469K	–	123
2018 Q3	$469K	Sell	6,012 -2,341	-28%	-$216K	0.01%	106
2018 Q2	$819K	Hold	8,353	–	–	0.02%	100
2018 Q1	$835K	Hold	8,353	–	–	0.02%	111
2017 Q4	$635K	Hold	8,353	–	–	0.02%	113
2017 Q3	$668K	Hold	8,353	–	–	0.03%	110
2017 Q2	$518K	Hold	8,353	–	–	0.03%	113
2017 Q1	$585K	Hold	8,353	–	–	0.03%	108
2016 Q4	$635K	Buy	8,353 +1,628	+24%	+$515K	0.05%	106
2016 Q3	$2.51M	Sell	6,725 -150	-2%	-$52.8K	0.16%	82
2016 Q2	$2.21M	Hold	6,875	–	–	0.15%	82
2016 Q1	$2.13M	Hold	6,875	–	–	0.19%	86
2015 Q4	$4.26M	Hold	6,875	–	–	0.32%	56
2015 Q3	$3.83M	Hold	6,875	–	–	0.31%	64
2015 Q2	$4.91M	Hold	6,875	–	–	0.3%	66
2015 Q1	$3.2M	Hold	6,875	–	–	0.25%	69
2014 Q4	$2.86M	Buy	+6,875	New	+$2.77M	0.24%	75

Other funds holding TARA

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PFMU

Privium Fund Management (UK) London, United Kingdom $197M AUM 0.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Perceptive Advisors's TARA Position: Q2 2023 in Review

Perceptive Advisors sold out of Protara Therapeutics (TARA) in Q2 2023, closing a stake of 290,051 shares — an estimated $908K sold.

Perceptive Advisors first reported a position in TARA in Q4 2014 and held it in 29 quarters. The position peaked at $14.7M in Q4 2020. 29 funds tracked by Wall St. Rank hold TARA as of Q2 2023.

Perceptive Advisors reported no remaining Protara Therapeutics position as of Q2 2023 after selling out during the quarter.
Perceptive Advisors sold 290,051 Protara Therapeutics shares in Q2 2023, an estimated $908K.
Perceptive Advisors first reported a position in Protara Therapeutics in Q4 2014 and held it in 29 quarters.
Perceptive Advisors's Protara Therapeutics position peaked at $14.7M in Q4 2020.
29 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2023.

Based on Perceptive Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.